3 Generic Formulations Maker, Latin America Branded Generics Seller and Leading Chronic Therapy Pharma Company Stocks With a Strong Future Roadmap: Alembic Pharmaceuticals, Caplin Point Laboratories and Torrent Pharmaceuticals
- October 28, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Alembic Pharmaceuticals, Caplin Point Laboratories and Torrent Pharmaceuticals: ROE of 11.9% to 25.5% and FY22 to FY26 revenue CAGR of 8.4% to 15.2%. Prices as of 27 Oct 2026.
Quick Answer
The three chronic therapy and generic formulation stocks to watch are Alembic Pharmaceuticals, Caplin Point Laboratories and Torrent Pharmaceuticals. Their return on equity ranges from 11.9% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 15.2%. Torrent Pharmaceuticals has the highest return on equity at 25.5%, while Caplin Point Laboratories has the fastest revenue growth at 15.2% a year. Prices are based on the 27 October 2026 close, and this article is educational, not investment advice.
Chronic therapy and generic formulation stocks offer a focused view of a sector where demand keeps widening. Alembic Pharmaceuticals, Caplin Point Laboratories and Torrent Pharmaceuticals cover a generic formulations maker, a Latin America focused branded generics seller and a leading chronic therapy pharma company.
This list covers three chronic therapy and generic formulation stocks with complete current figures: Alembic Pharmaceuticals, Caplin Point Laboratories and Torrent Pharmaceuticals. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Chronic Therapy and Generic Formulation Stocks?
Chronic therapy and generic formulation stocks are listed pharmaceutical companies that make branded and generic medicines for India, the United States and emerging markets. Their earnings depend on product launches, regulatory approvals, pricing and capacity use.
Chronic Therapy and Generic Formulation Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Alembic Pharmaceuticals | 766.9 | 14,914 | 21.6 | 35.7 | 11.9 | 0.25 |
| Caplin Point Laboratories | 2,352.4 | 17,194 | 25.4 | 36.0 | 17.9 | 0.00 |
| Torrent Pharmaceuticals | 4,625 | 173,079 | 80.3 | 36.0 | 25.5 | 1.79 |
On valuation, Alembic Pharmaceuticals and Caplin Point Laboratories trade at a P/E below the industry P/E, while Torrent Pharmaceuticals trades above it, which reflects the growth the market already expects. Readers comparing chronic therapy and generic formulation stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in chronic therapy and generic formulation stocks can use the coming numbers to test whether growth is holding.
Why Do Chronic Therapy and Generic Formulation Stocks Have a Strong Roadmap in India?
Chronic therapy and generic formulation stocks have a strong roadmap in India because rising healthcare spending, new drug launches and growing chronic care demand keep widening the market for Indian pharma companies.
- Product launches. New medicines add to the revenue base.
- Chronic care. Long-term therapies bring repeat demand.
- Export markets. Regulated and emerging markets widen reach.
Why Alembic Pharmaceuticals Features Among These Chronic Therapy and Generic Formulation Stocks
Among the chronic therapy and generic formulation stocks on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.
In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%.
Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.
Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.
Why Caplin Point Laboratories Features Among These Chronic Therapy and Generic Formulation Stocks
Among the branded generics and chronic pharma shares on this list, Caplin Point Laboratories, based in Chennai, sells branded generic medicines in Latin America and other emerging markets and has built a regulated-market business through its sterile injectables arm.
The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0.
Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore.
Roadmap: The company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.
What to watch: Follow new US product approvals and currency trends in Latin American markets.
Why Torrent Pharmaceuticals Features Among These Chronic Therapy and Generic Formulation Stocks
Among the three companies on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.
Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%.
In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.
Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.
What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.
Alembic Pharmaceuticals vs Caplin Point Laboratories vs Torrent Pharmaceuticals on Key Financials
The table below sets the three chronic therapy and generic formulation stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Alembic Pharmaceuticals | 5,356 | 7,399 | 8.4% | 671 | 9.1% |
| Caplin Point Laboratories | 1,308 | 2,303 | 15.2% | 650 | 28.2% |
| Torrent Pharmaceuticals | 8,705 | 13,886 | 12.4% | 2,138 | 15.4% |
Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Torrent Pharmaceuticals has the largest FY26 revenue at Rs 13,886 crore, and Caplin Point Laboratories shows the fastest revenue growth with a 15.2% compound annual rate. A useful habit with chronic therapy and generic formulation stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Alembic Pharmaceuticals | 1,717 | 2,165 | 26.1% |
| Caplin Point Laboratories | 533 | 644 | 20.7% |
| Torrent Pharmaceuticals | 3,141 | 4,909 | 56.3% |
Key Risks to Check Before Investing in Chronic Therapy and Generic Formulation Stocks
Every theme carries risks that deserve a check before any decision. For these chronic therapy and generic formulation stocks, the main points are: Long-term branded generics and chronic pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections can affect supply.
- Pricing pressure. Generic prices can vary across markets.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter chronic therapy and generic formulation stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Chronic Therapy and Generic Formulation Stocks
Chronic therapy and generic formulation stocks reward patient research into demand, execution and financial strength. Alembic Pharmaceuticals, Caplin Point Laboratories and Torrent Pharmaceuticals each have a clear plan to expand. Based on the 27 October 2026 close, Alembic Pharmaceuticals trades at Rs 766.9, Caplin Point Laboratories at Rs 2,352.4 and Torrent Pharmaceuticals at Rs 4,625. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these chronic therapy and generic formulation stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track chronic therapy and generic formulation stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are chronic therapy and generic formulation stocks?
Ans. Chronic therapy and generic formulation stocks are listed pharmaceutical companies that make branded and generic medicines for India, the United States and emerging markets. Their earnings depend on product launches, regulatory approvals, pricing and capacity use. This list looks at three of them, Alembic Pharmaceuticals, Caplin Point Laboratories and Torrent Pharmaceuticals, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.
Which chronic therapy and generic formulation stocks are covered in this list?
Ans. This list covers Alembic Pharmaceuticals, Caplin Point Laboratories and Torrent Pharmaceuticals. Based on the 27 October 2026 close, Alembic Pharmaceuticals traded at Rs 766.9, Caplin Point Laboratories at Rs 2,352.4 and Torrent Pharmaceuticals at Rs 4,625. Their return on equity ranges from 11.9% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 15.2%.
Why do chronic therapy and generic formulation stocks have a strong future roadmap in India?
Ans. Chronic therapy and generic formulation stocks have a strong roadmap in India because rising healthcare spending, new drug launches and growing chronic care demand keep widening the market for Indian pharma companies. The main drivers are as follows. Product launches. New medicines add to the revenue base. Chronic care. Long-term therapies bring repeat demand. Export markets. Regulated and emerging markets widen reach. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Alembic Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
How has Caplin Point Laboratories performed financially?
Ans. Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0. Looking ahead, the company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.
How has Torrent Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.
What risks should investors check before buying chronic therapy and generic formulation stocks?
Ans. Investors should check a few risks before buying chronic therapy and generic formulation stocks. Regulatory checks. Plant inspections can affect supply. Pricing pressure. Generic prices can vary across markets. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of chronic therapy and generic formulation stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.